



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On Jan. 8, 2003

DELTAGEN, INC.

By: Deborah A. Mojarro

Deborah A. Mojarro

PATENT
Attorney Docket No.: R-372

RECEIVED
JAN 15 2003
TECH CENTER 1600/2900

#13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KEITH D. ALLEN et al.

Application No.: 09/900,754

Filed: July 6, 2001

For: Transgenic Mice Containing
Tryptase Gene Disruptions

Examiner: Sita S. Pappu

Art Unit: 1632

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached Form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue there from.

Each item of information contained in the information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that

any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and MPEP § 609 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge our Deposit Account No. 50-1271 for any fees required in connection with the filing of this Information Disclosure Statement. **A duplicate copy of this Notice is enclosed for this purpose.** In particular, in the event that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is authorized to charge the above-named deposit account for any fees required pursuant to CFR § 1.17(p) or § 1.17(i)(1).

Respectfully submitted,


Mariette A. Lapiz, Reg. No. 44,282

DELTAGEN, INC.
740 Bay Road
Redwood City, CA 94063
Tel: 650-569-5100
Fax: 650-569-5280

MAL/dam

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/900,754
Filing Date	July 6, 2001
First Named Inventor	Keith D. Allen
Art Unit	1632
Examiner Name	Sita S. Pappu
Attorney Docket No.	R-372

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	A	WO	98/54307	A1	12/03/1998	Schering Aktiengesellschaft	whole document	
	B	WO	98/11238	A3	03/19/1998	Dana-Farber Cancer Inst.	whole document	
	C	WO	00/36910	A1	06/29/2000	Albert Einstein College of Medicine	Pages 2, 24; fig. 1	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D	G. WONG et al., "Cloning of the Human Homolog of Mouse Transmembrane Tryptase" Int'l. Arch. Allergy Immunology, Vol. 118, pp. 419-421 (1999)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.